


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-2. (Cancelled)
3. (Previously Presented) A compound according to claim 6, in which
A or B in each case independently of one another represent hydrogen, tetrazolyl or the group $-\text{N}(\text{CH}_3)_2$, $-\text{NH}(\text{CO})\text{-pyrrolidinyl}$, $-\text{NH}(\text{CO})\text{-pentyl}$, $-\text{NH}(\text{CO})\text{-hexyl}$, $-\text{NH}(\text{CO})\text{-hexyl-NH}_2$, $-\text{NH}(\text{CO})\text{-C}_3\text{H}_7$, $-\text{NH}(\text{CO})\text{-CH}_2\text{-phenyl}$, $-\text{NH}(\text{CO})\text{-CH}_2\text{-NH}_2$, $-\text{NH}(\text{CO})\text{-C}_2\text{H}_4\text{-NH}_2$, $-\text{NH}(\text{CO})\text{-CH}(\text{NH}_2)\text{-CH}_3$, $-\text{NH}(\text{CO})\text{-CH}(\text{NH}_2)\text{-hydroxyphenyl}$, $-\text{NH}(\text{CO})\text{-CH}(\text{NH}_2)\text{-CH}_2\text{-phenyl}$, $-\text{NH}(\text{CO})\text{-CH}(\text{NH}_2)\text{-CH}_2\text{-hydroxyphenyl}$, $-\text{NH}(\text{CO})\text{-CH}(\text{NH}(\text{CO})\text{-CH}_3)\text{-CH}_2\text{-phenyl}$, $-\text{NH}(\text{CO})\text{-CH}_2\text{-NH}(\text{CO})\text{-CH}_3$, $-\text{NH}(\text{CO})\text{-N}(\text{C}_2\text{H}_5)(\text{C}_2\text{H}_4\text{-piperidinyl})$, $-\text{NH}(\text{CO})\text{-N}(\text{CH}_3)(\text{C}_2\text{H}_4\text{-piperidinyl})$, $-\text{NH}(\text{CO})\text{-CH}_2\text{-NH}(\text{CH}_3)$, $-\text{CH}_2\text{-N}(\text{CH}_3)_2$, $-\text{NH}(\text{CO})\text{NH-CH}_2\text{-COOH}$, $-\text{CH}_2\text{-COOH}$ wherein pyrrolidinyl can optionally be substituted with hydroxy or the group $-\text{NH}_2$, $-\text{N}(\text{CH}_3)_2$ or $-\text{NH}(\text{CO})\text{-CH}_3$, and wherein hydantoinyl can be substituted with $-\text{CH}_3$, $-\text{CH}_2\text{-COOH}$, or $-(\text{CO})\text{-thiazolidinonyl}$,
X represents or the group $-\text{NH-}$,
R¹ represents halogen and
R² represents hydrogen or the group $-\text{NH}(\text{CO})\text{-phenyl}$
or $-\text{C}_2\text{H}_4\text{-}$, $-\text{C}_3\text{H}_6\text{-}$ both can optionally be substituted in one or more places, the same way or differently, with cyano, hydroxy, phenyl, naphthyl, imidazolyl, thiazolyl, pyridyl, 2-oxazoliny, piperidinyl, $-\text{NH}_2$, $-\text{NH-CH}_2\text{-thienyl}$, $-\text{NH-pyridinyl-NO}_2$, $-\text{NH-thiazolyl}$, $-\text{SO}_2\text{-thienyl}$, $-\text{SO}_2\text{-NH}_2$, $-\text{SO}_2\text{-CH}_3$, $-\text{SO}_2\text{-C}_3\text{H}_7$, pyrrolidinonyl substituted with $-\text{COOH}$, $-\text{NH}(\text{CO})\text{-NH-thienyl}$, $-\text{NH}(\text{CO})\text{-NH-phenyl}$, $-\text{NH}(\text{CO})\text{-NH-C}_2\text{H}_5$, $-\text{NH}(\text{CO})\text{-C}(\text{CH}_3)_3$, $-\text{NH}(\text{CO})\text{-S-C}_2\text{H}_5$, $-\text{NH}(\text{CS})\text{-NH-C}_2\text{H}_5$, $-\text{NH}(\text{CO})\text{-C}_2\text{H}_5$, $-\text{NH}(\text{CO})\text{-thienyl}$, $-(\text{CO})\text{-NH-NH}_2$, $-(\text{CO})\text{-NH-CH}_2\text{-}$

(CO)-NH₂, -(CO)-NH-C₂H₅, -COOH, wherein phenyl or imidazolyl, thiazolyl can optionally be substituted in one or more places, the same way or differently, with hydroxy, -CH₃, -NH-(CO)-CH₂-NH₂, -COOC₂H₅, -COOC(CH₃)₃,



or a diastereomer, enantiomer or pharmaceutically acceptable salt thereof.


4. (Previously Presented) A compound according to claim 6, in which
A or B in each case independently of one another represent hydrogen or the group -NH-

(CO)-pyrrolidinyl, -NH-(CO)-piperidinyl, -NH-(CO)-morpholinyl, -NH-(CO)-hexyl-NH₂, -NH-(CO)-CH(NH₂)-hydroxyphenyl, -NH-(CO)-CH(NH₂)-CH₂-hydroxyphenyl, hydantoin optionally substituted with -CH₃,

X represents or the group -NH-,

R¹ represents halogen and

R² represents hydrogen, -C₂H₄-imidazolyl or -C₃H₇ which can optionally be substituted in one or more places, the same way or differently with the group -NH-CH₂-thienyl, -NH-(CO)-C₂H₅, -NH-(CO)-C(CH₃)₃,




or a diastereomer, enantiomer or pharmaceutically acceptable salt thereof.

5. (Currently Amended) A compound according to claim 4, which is
N-[3-[[5-bromo-4-[[3-[[[1-(trifluoromethyl)cyclobutyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
N-[3-[[5-bromo-4-[[3-[[1-oxo-3-(phenylsulfonyl)propyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
N-[3-[[4-[[3-[[[1-aminocyclopentyl]carbonyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
N-[3-[[4-[[3-[[[1-aminocyclobutyl]carbonyl]amino]propyl]amino]-5-iodo-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
N'-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-1,1-cyclopentanedicarboxamide,
(4R)-N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,
(4R)-N-[3-[[5-bromo-2-[[3-(3-methyl-2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,
3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,
3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-1-methyl-2,4-imidazolidinedione,
N'-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-N-ethyl-N-[2-(1-piperidinyl)ethyl]-urea,
N-[3-[[5-bromo-4-[[3-[(2,2-dimethyl-1-oxopropyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
N-[3-[[2-[[3-[[[(2S)-2-amino-3-(4-hydroxyphenyl)-1-oxopropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,

N-[3-[[2-[[3-[(1-aminocyclohexyl)carbonyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
 N-[3-[[2-[[3-[(2S)-2-amino-2-phenylacetyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
 N-[3-[[2-[[3-[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-5-oxo-2-pyrrolidinecarboxamide,
 N-[3-[[2-[[3-[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
 N¹-[3-[[5-bromo-2-[[3-[(2S)-2-pyrrolidinylcarbonyl]amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-1,1-cyclopropanedicarboxamide,
 N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
 N-(3-((5-bromo-4-((2-(1*H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-4-morpholinecarboxamide,
 N-(3-((5-bromo-4-((2-(1*H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,
 N-(3-((5-bromo-4-((3-((2-thienylcarbonyl)amino)propyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,
 N1-(3-((5-bromo-2-((3-((1-pyrrolidinylcarbonyl)amino)phenyl)amino)-4-pyrimidinyl)-amino)propyl)-1,1-cyclopropanedicarboxamide,
 N-(3-((5-bromo-4-((3-((1-oxopropyl)amino)propyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,
 N-(3-((5-iodo-4-((3-((2-thienylcarbonyl)amino)propyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,
 N-[3-[[5-bromo-4-[[3-[[[(2S)-5-oxo-2-pyrrolidinyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
 N-[3-[[5-bromo-4-[[3-[[[(2S)-4-oxo-2-azetidyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
 (4R)-N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide or


N-[3-[[4-[[3-[[[(1-aminocyclobutyl)carbonyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
or a pharmaceutically acceptable salt thereof.

6. (Currently Amended) A compound of formula (I)



in which

- A or B in each case independently of one another represent hydrogen or the group $-\text{NO}_2$, $-\text{NH}_2$, $-\text{NR}^3\text{R}^4$, $-\text{N}(\text{C}_{1-6}\text{-hydroxyalkyl})_2$, $-\text{NH}(\text{CO})-\text{R}^5$, $-\text{NHCOOR}^6$, $-\text{NR}^7-(\text{CO})-\text{NR}^8\text{R}^9$, $-\text{NR}^7-(\text{CS})-\text{NR}^8\text{R}^9$, $-\text{CO}-\text{NR}^8\text{R}^9$, $-\text{SO}_2-\text{CH}_3$, 4-bromo-1-methyl-1*H*-pyrazolo-3-yl or C_{1-6} -alkyl optionally substituted in one or more places, the same way or differently with cyano, halogen, hydroxy or the group $-\text{NH}_2$, $-\text{NH}(\text{CO})-\text{R}^5$, $-\text{SO}_2-\text{NHR}^3$, $-\text{COOR}^5$, $-\text{CONR}^8\text{R}^9$, $-\text{O}(\text{CO})-\text{R}^5$, $-\text{O}(\text{CO})-\text{C}_{1-6}\text{-alkyl}-\text{R}^5$,
- X represents an oxygen atom or the group $-\text{NH}-$,
- R^1 represents ~~hydrogen, halogen, hydroxymethyl or the group $-\text{COOH}$, $-\text{COO}$ iso-propyl, $-\text{NO}_2$, $-\text{NH}(\text{CO})(\text{CH}_2)_2-\text{COOH}$ or $-\text{NH}(\text{CO})(\text{CH}_2)_2-\text{COO}-\text{C}_{1-6}\text{-alkyl}$,~~
- R^2 represents C_{1-6} -alkyl optionally substituted in one or more places, the same way or differently, with hydroxy, imidazolyl or the group $-\text{NH}_2$, $-\text{NH}(\text{CO})\text{O}-\text{CH}_2$ -phenyl, $-\text{NH}(\text{CO})\text{H}$, $-\text{NH}(\text{CO})$ -phenyl, $-\text{NH}(\text{CO})-\text{CH}_2$ -O-phenyl, $-\text{NH}(\text{CO})-\text{CH}_2$ -phenyl, $-\text{NH}(\text{CO})-\text{CH}(\text{NH}_2)\text{CH}_2$ -phenyl, $-\text{NH}(\text{CO})-\text{CH}_2-\text{CH}(\text{CH}_3)$ -phenyl, $-\text{NH}(\text{CO})-\text{CH}(\text{NH}_2)-(\text{CH}_2)_2-\text{COOH}$,



wherein phenyl can optionally be substituted in one or more places, the same or differently with halogen, C₁₋₆-alkyl or $-(CO)-C(CH_3)_2-C_2H_5$, ~~or represents C₃-alkynyl~~,

R³ or R⁴ in each case independently of one another represent hydrogen or C₁₋₆-alkyl optionally substituted in one or more places, the same way or differently, with hydroxy, phenyl or hydroxyphenyl,

or

R³ and R⁴ together form a C₃₋₆-heterocycloalkylring containing at least one nitrogen atom and optionally can be interrupted by one or more oxygen and/or sulfur atoms and/or can be interrupted by one or more $-(CO)-$ groups in the ring and/or optionally can contain one or more possible double bonds in the ring, wherein the C₃₋₆-heterocycloalkylring can optionally be substituted with C₁₋₆-alkyl, C₁₋₆-alkyl-COOH or C₁₋₆-alkyl-NH₂,

R⁵ represents C₁₋₆-alkyl, C₂₋₆-alkenyl, C₃₋₆-cycloalkyl or phenyl each can optionally be substituted in one or more places, the same way or differently, with halogen, hydroxy, phenyl or with the group $-NH_2$, $-NH(CO)-O-C_{1-6}$ -alkyl, wherein phenyl can optionally be substituted in one or more places, the same way or differently, with halogen, hydroxy or C₁₋₆-alkyl,


R⁶ represents C₁₋₆-alkyl, C₂₋₆-alkenyl or phenyl,

R^7 represents hydrogen or C_{1-6} -alkyl and
 R^8 or R^9 in each case independently of one another represent hydrogen, C_{1-6} -alkyl, C_{2-6} -alkenyl, C_{3-6} -cycloalkyl, aryl or phenyl, wherein aryl or phenyl can optionally be substituted in one or more places, the same way or differently, with hydroxy or the group $-NO_2$ or $-N(C_{1-6}\text{-alkyl})_2$
or
 R^8 and R^9 together form a C_{3-6} -heterocycloalkylring containing at least one nitrogen atom and optionally can be interrupted by one or more oxygen and/or sulfur atoms and/or can be interrupted by one or more $-(CO)-$ groups in the ring and/or optionally can contain one or more possible double bonds in the ring, wherein the C_{3-6} -heterocycloalkylring can optionally be substituted with the group $-NH_2$,
~~wherein — when A and B represent hydrogen, X represents $-NH-$ and R^2 represents C_{1-6} -alkyl,~~
~~then R^1 represents $-NH-(CO)-CH(NH_2)-(CH_2)_2-COOH$ or $-NH-(CO)-CH(NH_2)-(CH_2)_2-COOC_2H_5$,~~
~~wherein — when R^1 represents $-COO$ -iso-propyl,~~
~~then X represents $-NH-$ and R^2 represents C_3 -alkinyl and A or B independently of one another represent the group $-NO_2$ or $-NH-(CO)-CF_3$, and~~
~~wherein — when R^1 represents halogen, X represents $-NH-$, B represents hydrogen and R^2 represents C_{1-6} -alkyl substituted with $-NH_2$,~~
~~then A represents $-NH-(CO)-C_6$ -cycloalkyl- NH_2 ,~~
or a diastereomer, enantiomer or pharmaceutically acceptable salt thereof.

7. (Currently Amended) A compound according to claim 6, in which
A or B in each case independently of one another represent hydrogen or the group $-NH-$, C_2H_4-OH , $-NH-CH_2$ -hydroxyphenyl, $-NH-(CO)$ -pyrrolidinyl, $-NH-(CO)-CH(NH_2)-CH_2$ -phenyl, $-NH-(CO)$ -pentyl- NH_2 , $-NH-(CO)$ -hexyl- NH_2 , $-NH-(CO)-CH_2-NH_2$, $-NH-(CO)-CH(NH_2)$ -hydroxyphenyl, $-NH-(CO)-CH_2$ -hydroxyphenyl, $-NH-(CO)-CH_2$ -methylphenyl, $-NH-(CO)-C_2H_4$ -dihydroxyphenyl, $-NH-(CO)-CH(OH)$ -phenyl, $-NH-(CO)-CH(NH_2)-CH_2(OH)$, $-NH-(CO)-C(CH_3)_2NH_2$, $-NH-$

(CO)-NH(C₂H₅), -CH₂OH, -(CO)-NH-cyclopropyl, -(CO)-NH-CH(CH₃)₂,
 wherein pyrrolidinyl can optionally be substituted with hydroxy or the group -
 NH₂,

X represents an oxygen atom or the group -NH-,
 R¹ represents halogen or hydroxymethyl and
 R² represents -C₂H₅ optionally substituted in one or more places, the same way or
 differently, with hydroxy, imidazolyl
 or represents -C₃H₇ or -C₄H₈ optionally substituted in one or more places, the
 same way or differently with the group -NH₂, -NH-(CO)-CH(NH₂)-C₂H₄-COOH,
 -NH-(CO)-phenyl, -NH-(CO)-CH₂-phenyl, -NH-(CO)-CH₂-CH(CH₃)-phenyl, -
 NH-(CO)-CH₂-O-phenyl, -NH-(CO)-O-CH₂-phenyl, -NH-(CO)-CH(NH₂)CH₂-
 phenyl,



wherein phenyl can optionally be substituted in one or more places, the same or
 differently, with halogen, -CH₃ or -(CO)-C(CH₂)(C₂H₅),
 or represents -C₃-alkinyl,

or a diastereomer, enantiomer or pharmaceutically acceptable salt thereof.

8. (Currently Amended) A compound according to claim 7, which is
N-[3-[[2-[[3-[[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
1-[3-[[2-[[3-[[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2-oxo-3-pyrrolidinecarboxylic acid,
N-[3-[[5-bromo-4-[[3-[[[(5-oxo-2-pyrrolidiny]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[2-(2,4-dichloro-phenyl)-acetylamino]-propylamino}-pyrimidin-2-ylamino)-phenyl]-amide,
Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[2-(4-bromo-phenyl)-acetylamino]-propylamino}-pyrimidin-2-ylamino)-phenyl]-amide,
Pyrrolidine-1-carboxylic acid (3-{5-bromo-4-[3-(2-p-tolyl-acetylamino)-propylamino]-pyrimidin-2-ylamino}-phenyl)-amide,
Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[2-(2,4-difluoro-phenyl)-acetylamino]-propylamino}-pyrimidin-2-ylamino)-phenyl]-amide,
Pyrrolidine-1-carboxylic acid {3-[5-bromo-4-(3-{2-[2,3-dichloro-4-(2-methylene-butyl)-phenoxy]-acetylamino}-propylamino)-pyrimidin-2-ylamino]-phenyl}-amide,
Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[3-(2,3-dichloro-phenyl)-butyrylamino]-propylamino}-pyrimidin-2-ylamino)-phenyl]-amide,
Pyrrolidine-1-carboxylic acid (3-{5-bromo-4-[3-(3-bromo-benzoylamino)-propylamino]-pyrimidin-2-ylamino}-phenyl)-amide,
N-(3-((4-((4-aminobutyl)amino)-5-bromo-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,
N-[3-[[2-[[3-[[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
N-[3-[[[(2*S*)-2-Amino-1-oxo-3-phenylpropyl]amino]-5-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide,
N-[3-[[[(2*R*)-2-Amino-1-oxo-3-phenylpropyl]amino]-5-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide,
(α R)- α -Amino-*N*-[3-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]-5-

(hydroxymethyl)phenyl]benzenepropanamide,
 2-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-5-hydroxymethyl-phenylamino]-
 ethanol,
 (2R)-Amino-N-[3-hydroxymethyl-5-(4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-phenyl-
 propionamide,
 3-((2R)-Amino-3-phenyl-propionylamino)-5-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-
 ylamino)- N-cyclopropyl-benzamide,
 3-((2R)-Amino-3-phenyl-propionylamino)-5-(5-bromo-4-prop-2-ynyloxy-pyrimidin-2-ylamino)-
 N-isopropyl-benzamide,
 Phenylmethyl [3-[[2-[[3-[[[(ethylamino)carbonyl]amino]phenyl]amino]-5-
 (hydroxymethyl)pyrimidine-4-yl]amino]propyl]carbamate,
 Pyrrolidine-1-carboxylic acid (3-{4-[3-((2R)-amino-3-phenyl-propionylamino)-propylamino]-5-
 bromo-pyrimidine-2-ylamino}-phenyl)-amide,
 Pyrrolidine-1-carboxylic acid (3-{4-[3-((2S)-amino-3-phenyl-propionylamino)-propylamino]-5-
 bromo-pyrimidine-2-ylamino}-phenyl)-amide,
 2-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenylamino]-ethanol,
 1-Amino-cyclopentancarbonylic acid[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-
 phenyl]-amide,
 1-Amino-cyclohexancarbonylic acid-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-
 phenyl]-amide,
 (2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-phenyl-
 propionamide,
 (2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-phenyl-
 propionamide,
 2-{[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenylamino]-methyl}-phenol,
 (2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-(4-hydroxy-
 phenyl)-propionamide,
 N-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-(3,4-dihydroxy-phenyl)-
 propionamide,
 N-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-2-hydroxy-(2S)-phenyl-

acetamide,

N-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-2-hydroxy-(2R)-phenyl-
acetamide,

(2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-hydroxy-
propionamide,

(2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidin-2-ylamino)-phenyl]-3-hydroxy-
propionamide,

2-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-2-methyl-
propionamide,

(2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-(4-hydroxy-
phenyl)-propionamide,


(2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-p-tolyl-
propionamide or

(2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-p-tolyl-
propionamide,

or a pharmaceutically acceptable salt thereof.

9. (Currently Amended) A compound according to claim 6, in which
- A or B in each case independently of one another represent ~~halogen~~, hydrogen or the group -SO₂-CH₃, -NO₂, -NH₂, -CF₃, -CH₂-NH-(CO)-NH₂, -CH₂-pyrrolidinyl, -NH-(CO)-CH₃, -NH-(CO)-hexyl-NH₂, -NH-(CO)-phenyl, -NH-(CO)-pyrrolidinyl, --NH-(CO)-CH(NH₂)-CH₂-phenyl, NH-(CO)-OCH₃, -NH-(CO)-OCH(CH₃)₂, -NH-(CO)-OC₂H₄-morpholino, -NH-(CO)-NH-cyclopropyl, -NH-(CO)-morpholino, -NH-(CO)-NH-C₂H₄-morpholino, -NH-(CO)-NH-hydroxycycloalkyl, hydantoinyl,
- wherein pyrrolidinyl can optionally be substituted with hydroxy or the group -NH₂ and
- wherein hydantoinyl can optionally be substituted with the group -CH₃ or -(CO)-thiazolidinonyl,
- X represents the group -NH-,

R¹ represents halogen and
 R² represents -CH₂-dihydroxyphenyl, -C₂H₄-imidazolyl, or -C₃H₇ optionally substituted in one or more places, the same way or differently, with



or a diastereomer, enantiomer or pharmaceutically acceptable salt thereof.

10. (Previously Presented) A compound, which is
 4-((4-((2-(1H-imidazol-4-yl)ethyl)amino)-5-iodo-2-pyrimidinyl)amino)-benzenesulfonamide,
 N-((3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)methyl)-
 urea,
 1-((3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)methyl)-3-
 pyrrolidinol,
 (3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-carbamic acid
 methyl ester,
 N2-(3-aminophenyl)-5-bromo-N4-(2-(1H-imidazol-4-yl)ethyl)-2,4-pyrimidinediamine,
 N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-N'-
 cyclopropyl-urea,
 N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-4-
 morpholinecarboxamide,
 (3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-carbamic acid
 1-methylethyl ester,
 N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-
 methanesulfonamide,

N2-(3-amino-5-(trifluoromethyl)phenyl)-5-bromo-N4-(2-(1H-imidazol-4-yl)ethyl)-2,4-pyrimidinediamine,
 N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-N'-(2-(4-morpholinyl)ethyl)-urea,
 N2-(3-amino-5-chlorophenyl)-5-bromo-N4-(2-(1H-imidazol-4-yl)ethyl)-2,4-pyrimidinediamine,
 (3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-carbamic acid 2-(4-morpholinyl)ethyl ester,
 N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-N'-(4-hydroxycyclohexyl)-urea,
 N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-acetamide,
 N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-benzamide,
 (4R)-N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,
 3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,
 3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-1-methyl-2,4-imidazolidinedione,
 1-[3-[[2-[[3-[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2-oxo-3-pyrrolidinecarboxylic acid,
 1-[3-[[2-[[3-[(1-aminocyclohexyl)carbonyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2-oxo-3-pyrrolidinecarboxylic acid,
 N-[3-[[2-[[3-[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-5-oxo-2-pyrrolidinecarboxamide,
 N-[3-[[2-[[3-[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-chloro-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
 3-[3-[[5-bromo-4-[(3,4-dihydroxyphenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,
 3-[3-[[5-bromo-4-[(3,4-dihydroxyphenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-1-methyl-2,4-imidazolidinedione,
 (4R)-N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-

pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,
 N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-
 5-oxo-2-pyrrolidinecarboxamide,
 N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-
 2,2-dimethyl-propanediamide,
 3-[3-[[5-bromo-4-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-
 imidazolidinedione,
 (4R)-N-[3-[[5-bromo-2-[[3-(3-methyl-2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-
 pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide or
 (4R)-N-[3-[[5-bromo-2-[[3-[2,5-dioxo-3-[[4R)-2-oxo-4-thiazolidinyl]carbonyl]-1-
 imidazolidinyl]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,
 or a pharmaceutically acceptable salt thereof.

11. (Previously Presented) A compound, which is
 N-(3-((4-((3-(aminomethyl)phenyl)amino)-5-bromo-2-pyrimidinyl)amino)phenyl)-1-pyrrolidine-
 carboxamide,
 4-[[5-bromo-4-[[2-(1H-imidazol-5-yl)ethyl]amino]-2-pyrimidinyl]amino]-1-naphthaleneacetic
 acid,
 5-[[5-bromo-4-[[2-(1H-imidazol-5-yl)ethyl]amino]-2-pyrimidinyl]amino]-1H-indole-2-
 carboxylic acid, ethyl ester,
 5-bromo-N4-[2-(1H-imidazol-5-yl)ethyl]-N2-(2-methyl-6-quinoliny)-2,4-pyrimidinediamine,
 4-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzamide,
 4-((4-((2-(1H-imidazol-4-yl)ethyl)amino)-5-iodo-2-pyrimidinyl)amino)-benzenesulfonamide,
 3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzamide,
 3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,
 5-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-1,3-dihydro-2H-
 benzimidazol-2-one,
 3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)- benzoic acid methyl
 ester,
 3-amino-5-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)- benzoic acid

methyl ester,

N-((3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)methyl)-methanesulfonamide,

4-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)- benzoic acid methyl ester,

3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-phenol,

5-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-*1H*-isoindole-1,3(2H)-dione,

5-bromo-*N*⁴-(2-(*1H*-imidazol-4-yl)ethyl)-*N*²-(3-methylphenyl)-2,4-pyrimidinediamine,

N-(3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-methanesulfonamide,

4-((4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-5-methyl-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((4-((3-aminopropyl)amino)-5-bromo-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((5-bromo-4-((3-(*1H*-imidazol-1-yl)propyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((5-bromo-4-((2-(1-pyrrolidinyl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((4-((4-aminobutyl)amino)-5-bromo-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-butanoic acid,

4-((4-((3-((aminocarbonyl)amino)propyl)amino)-5-bromo-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-butanoic acid ethyl ester,

4-((5-bromo-4-((4-(methylamino)butyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((5-bromo-4-((2-(*1H*-imidazol-1-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((5-ethyl-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((5-bromo-4-((2-(2-pyridinyl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((5-bromo-4-((2-(*1H*-indol-3-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

2-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-acetamide,

N-(2-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)ethyl)-acetamide,
 3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-propanamide,
N-(4-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)butyl)-acetamide,
N-(3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)propyl)-acetamide,
N-(3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)propyl)-2-furancarboxamide,
N-(3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)propyl)-1*H*-pyrrole-2-carboxamide,
 4-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-butanamide,
N-(3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)propyl)-2-thiophenecarboxamide,
 4-((4-(4-(aminomethyl)-1-piperidinyl)-5-bromo-2-pyrimidinyl)amino)-benzenesulfonamide,
 4-(5-bromo-4-prop-2-ynylamino-pyrimidin-2-ylamino)-phenyl]-*N,N*-dimethylaminosulfonylamin,
 1-Methyl-1*H*-imidazol-4-sulfonic acid [4-(5-bromo-4-prop-2-ynylamino-pyrimidin-2-ylamino)-phenyl]-amid,
 3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
 4-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
 2-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
 2-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenol,
 4-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid methyl ester,
 3-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-phenol,
 2-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
 3-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
 4-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
 4-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-phenol,
 Methyl 3-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]-5-[(2-hydroxyethyl)amino]benzoate,
 Methyl 3-amino-5-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]benzoate or
 3-[Bis-(2-hydroxy-ethyl)-amino]-5-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic

acid methyl ester,
or a pharmaceutically acceptable salt thereof.

12. (Previously Presented) A pharmaceutical composition comprising at least one compound according to claim 6 and a pharmaceutically acceptable carrier, diluent or excipient.

13-16. (Cancelled)

17. (Currently Amended) A method of treating ~~cancer~~ Kaposi sarcoma, Hodgkin's disease or leukemia comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 12.

18. (Cancelled)

19. (Previously Presented) A method according to claim 17, wherein the patient treated is a mammal.

20. (Previously Presented) A method of claim 19, wherein the mammal is a human.


21-25. (Cancelled)

26. (Previously Presented) A pharmaceutical composition comprising at least one compound according to claim 11 and a pharmaceutically acceptable carrier, diluent or excipient.

27. (Currently Amended) A method of treating ~~cancer~~ Kaposi sarcoma, Hodgkin's disease or leukemia comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 26.

28. (Cancelled)
29. (Previously Presented) A method of treating rheumatoid arthritis comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 12.
- 30-31. (Cancelled)
32. (Previously Presented) A compound according to claim 6, wherein X represents an oxygen atom.
33. (Previously Presented) A compound according to claim 6, wherein X represents the group -NH-.
34. (Previously Presented) A compound according to claim 6, wherein
A or B in each case independently of one another represent hydrogen or the group -NO₂, -NH₂, -NR³R⁴, -N(C₁₋₆-hydroxyalkyl)₂, -NH(CO)-R⁵, -NHCOOR⁶, -NR⁷-(CO)-NR⁸R⁹, -NR⁷-(CS)-NR⁸R⁹, -CO-NR⁸R⁹, -SO₂-CH₃, 4-bromo-1-methyl-1*H*-pyrazolo-3-yl or C₁₋₆-alkyl optionally substituted in one or more places, the same way or differently with cyano, hydroxy or the group -NH₂, -NH-(CO)-R⁵, -SO₂-NHR³, -COOR⁵, -CONR⁸R⁹, -O-(CO)-R⁵, -O-(CO)-C₁₋₆-alkyl-R⁵.
35. (Cancelled)
36. (Currently Amended) A compound according to claim 6, wherein
R² represents C₁₋₆-alkyl optionally substituted in one or more places, the same way or differently, with hydroxy, imidazolyl or the group -NH-(CO)O-CH₂-phenyl, -NH-(CO)H, -NH-(CO)-phenyl, -NH-(CO)-CH₂-O-phenyl, -NH-(CO)-CH₂-phenyl, -NH-(CO)-CH(NH₂)CH₂-phenyl, -NH-(CO)-CH₂-CH(CH₃)-phenyl, -NH-(CO)-


CH(NH₂)-(CH₂)₂-COOH,



wherein phenyl can optionally be substituted in one or more places, the same or differently with halogen, C₁₋₆-alkyl or -(CO)-C(CH₂)-C₂H₅, or represents C₃-alkynyl.

37-38. (Cancelled)

39. (New) A compound according to claim 6, wherein
 R² represents a straight chain or branched chain C₁₋₆-alkyl substituted in one or more places, the same way or differently, with hydroxy, imidazolyl or the group -NH₂, -NH-(CO)O-CH₂-phenyl, -NH-(CO)H, -NH-(CO)-phenyl, -NH-(CO)-CH₂-O-phenyl, -NH-(CO)-CH₂-phenyl, -NH-(CO)-CH(NH₂)CH₂-phenyl, -NH-(CO)-CH₂-CH(CH₃)-phenyl, -NH-(CO)-CH(NH₂)-(CH₂)₂-COOH,



wherein phenyl can optionally be substituted in one or more places, the same or differently with halogen, C₁₋₆-alkyl or $-(CO)-C(CH_2)-C_2H_5$.

40. (New) A pharmaceutical composition comprising at least one compound according to claim 39 and a pharmaceutically acceptable carrier, diluent or excipient.

41. (New) A method of treating Kaposi sarcoma, Hodgkin's disease or leukemia comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 12.